Methods Related to Wound Healing

• US 8,796,025 B2
• Filed: 05/08/2012
• Issued: 08/05/2014
• Est. Priority Date: 03/29/2006
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Emig, Charlotte A, Trumpower, Catherine J, Marshall, Vivienne S
• Primary Examiner(s): DRISCOLL, LORA E BARNHART
• Application Number:
  US13/466,169
• Publication Number:
  US 20120251526A1
• Time in Patent Office: 819 Days
• Field of Search: None
• US Class Current: 435/405
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0629 Keratinocytes; Whole skin

Abstract

The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.

Claims

1. A method for accelerating wound healing of a chronic, infected wound as compared to the healing rate of a non-treated chronic, infected wound in a patient in need thereof comprising treating the chronic, infected wound by topically administering to the patient'"'"'s chronic, infected wound 0.5 μ

L-2000 μ

L conditioned medium per cm² of chronic, infected wound, wherein the conditioned medium is made by

a) obtaining a placenta and isolating an amnion from the placenta;

b) enzymatically releasing amnion-derived epithelial cells from the amnion;

c) collecting the released amnion-derived epithelial cells;

d) culturing the collected amnion-derived epithelial cells of step (c) in basal culture medium that is supplemented with human serum albumin and human recombinant EGF; and

e) collecting the conditioned medium.

2. The method of claim 1 wherein the chronic, infected wound is selected from the group consisting of a pressure ulcer, a venous ulcer, a diabetic ulcer and a sickle cell ulcer.

3. The method of claim 1 wherein the conditioned medium is pooled conditioned medium.

4. The method of claim 1 wherein the conditioned medium is administered in combination with an active agent selected from the group consisting of a growth factor, a cytokine, a chemokine, an antibody, an antibiotic, an anti-fungal, and an anti-viral.